Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients.

Gosselt HR, van Zelst BD, de Rotte MCFJ, Hazes JMW, de Jonge R, Heil SG.

Arthritis Res Ther. 2019 Jun 26;21(1):157. doi: 10.1186/s13075-019-1936-5.

2.

Comparison of disease activity measures in early psoriatic arthritis in usual care.

Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Vis M.

Rheumatology (Oxford). 2019 Jun 18. pii: kez215. doi: 10.1093/rheumatology/kez215. [Epub ahead of print]

PMID:
31211399
3.

Altered DNA methylation in children born to mothers with rheumatoid arthritis during pregnancy.

Ince-Askan H, Mandaviya PR, Felix JF, Duijts L, van Meurs JB, Hazes JMW, Dolhain RJEM.

Ann Rheum Dis. 2019 Sep;78(9):1198-1204. doi: 10.1136/annrheumdis-2018-214930. Epub 2019 May 29.

4.

Response to: 'TARA Study: a new perspective on tapering drugs in RA' by Mishra et al.

van Mulligen E, Hazes JMW, Weel AEAM, de Jong PHP.

Ann Rheum Dis. 2019 May 20. pii: annrheumdis-2019-215641. doi: 10.1136/annrheumdis-2019-215641. [Epub ahead of print] No abstract available.

PMID:
31110029
5.

Cartilage evaluation in finger joints in healthy controls and early hand osteoarthritis patients using high-resolution MRI.

Saltzherr MS, Muradin GSR, Haugen IK, Selles RW, van Neck JW, Coert JH, Hazes JMW, Luime JJ.

Osteoarthritis Cartilage. 2019 Aug;27(8):1148-1151. doi: 10.1016/j.joca.2019.05.003. Epub 2019 May 18.

PMID:
31108225
6.

Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.

van Mulligen E, de Jong PHP, Kuijper TM, van der Ven M, Appels C, Bijkerk C, Harbers JB, de Man Y, Molenaar THE, Tchetverikov I, Goekoop-Ruiterman YPM, van Zeben J, Hazes JMW, Weel AEAM, Luime JJ.

Ann Rheum Dis. 2019 Jun;78(6):746-753. doi: 10.1136/annrheumdis-2018-214970. Epub 2019 Apr 6.

7.

The Development and Evaluation of Personalized Training in Shared Decision-making Skills for Rheumatologists.

Mahmood S, Hazes JMW, Veldt P, van Riel P, Landewé R, Moens HB, Pasma A.

J Rheumatol. 2019 Apr 1. pii: jrheum.180780. doi: 10.3899/jrheum.180780. [Epub ahead of print]

PMID:
30936289
8.

Association of Physical Activity and Medication with Enthesitis on Ultrasound in Psoriatic Arthritis.

Wervers K, Herrings I, Luime JJ, Tchetverikov I, Gerards AH, Hazes JMW, Vis M.

J Rheumatol. 2019 Oct;46(10):1290-1294. doi: 10.3899/jrheum.180782. Epub 2019 Mar 1.

PMID:
30824661
9.

Breastfeeding among Women with Rheumatoid Arthritis Compared with the General Population: Results from a Nationwide Prospective Cohort Study.

Ince-Askan H, Hazes JMW, Dolhain RJEM.

J Rheumatol. 2019 Sep;46(9):1067-1074. doi: 10.3899/jrheum.180805. Epub 2019 Mar 1.

PMID:
30824652
10.

Associations between antenatal prednisone exposure and long-term cortisol and cortisone concentrations in children born to women with rheumatoid arthritis: results from a nationwide prospective cohort study.

Ince-Askan H, van den Akker ELT, de Rijke YB, van Rossum EFC, Hazes JMW, Dolhain RJEM.

RMD Open. 2019 Jan 30;5(1):e000852. doi: 10.1136/rmdopen-2018-000852. eCollection 2019.

11.

Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis.

Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Vis M; Cicero.

Arthritis Res Ther. 2019 Jan 16;21(1):25. doi: 10.1186/s13075-019-1811-4.

12.

Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.

Eektimmerman F, Allaart CF, Hazes JM, den Broeder AA, Fransen J, Swen JJ, Guchelaar HJ.

Pharmacogenomics. 2019 Jan;20(2):85-93. doi: 10.2217/pgs-2018-0144. Epub 2019 Jan 10.

PMID:
30628539
13.

Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis.

de Rotte MCFJ, Pluijm SMF, de Jong PHP, Bulatović Ćalasan M, Wulffraat NM, Weel AEAM, Lindemans J, Hazes JMW, de Jonge R.

PLoS One. 2018 Dec 10;13(12):e0208534. doi: 10.1371/journal.pone.0208534. eCollection 2018.

14.

High-throughput Serum N-Glycomics: Method Comparison and Application to Study Rheumatoid Arthritis and Pregnancy-associated Changes.

Reiding KR, Bondt A, Hennig R, Gardner RA, O'Flaherty R, Trbojević-Akmačić I, Shubhakar A, Hazes JMW, Reichl U, Fernandes DL, Pučić-Baković M, Rapp E, Spencer DIR, Dolhain RJEM, Rudd PM, Lauc G, Wuhrer M.

Mol Cell Proteomics. 2019 Jan;18(1):3-15. doi: 10.1074/mcp.RA117.000454. Epub 2018 Sep 21.

PMID:
30242110
15.

1,25(OH)2D3 and dexamethasone additively suppress synovial fibroblast activation by CCR6+ T helper memory cells and enhance the effect of tumor necrosis factor alpha blockade.

Dankers W, González-Leal C, Davelaar N, Asmawidjaja PS, Mus AMC, Hazes JMW, Colin EM, Lubberts E.

Arthritis Res Ther. 2018 Sep 20;20(1):212. doi: 10.1186/s13075-018-1706-9.

16.

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.

Teitsma XM, Jacobs JWG, de Jong PHP, Hazes JMW, Weel AEAM, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29. No abstract available.

PMID:
30158123
17.

Successful implementation of a clinical transition pathway for adolescents with juvenile-onset rheumatic and musculoskeletal diseases.

Walter M, Kamphuis S, van Pelt P, de Vroed A, Hazes JMW.

Pediatr Rheumatol Online J. 2018 Aug 3;16(1):50. doi: 10.1186/s12969-018-0268-3.

18.

Fatigue in early, intensively treated and tight-controlled rheumatoid arthritis patients is frequent and persistent: a prospective study.

Walter MJM, Kuijper TM, Hazes JMW, Weel AE, Luime JJ.

Rheumatol Int. 2018 Sep;38(9):1643-1650. doi: 10.1007/s00296-018-4102-5. Epub 2018 Jul 16.

19.

Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis.

Wervers K, Luime JJ, Tchetverikov I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Vis M.

J Rheumatol. 2018 Nov;45(11):1526-1531. doi: 10.3899/jrheum.171406. Epub 2018 Jul 1.

PMID:
29961685
20.

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.

Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14.

PMID:
29760159
21.

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.

Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2018 Oct;70(10):1557-1564. doi: 10.1002/art.40546. Epub 2018 Aug 23.

22.

ACPA IgG galactosylation associates with disease activity in pregnant patients with rheumatoid arthritis.

Bondt A, Hafkenscheid L, Falck D, Kuijper TM, Rombouts Y, Hazes JMW, Wuhrer M, Dolhain RJEM.

Ann Rheum Dis. 2018 Aug;77(8):1130-1136. doi: 10.1136/annrheumdis-2018-212946. Epub 2018 Apr 3.

PMID:
29615411
23.

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.

Wervers K, Vis M, Tchetveriko I, Gerards AH, Kok MR, Appels CWY, van der Graaff WL, van Groenendael JHLM, Korswagen LA, Veris-van Dieren JJ, Hazes JMW, Luime JJ.

Arthritis Care Res (Hoboken). 2018 Dec;70(12):1764-1770. doi: 10.1002/acr.23571.

24.

From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?

Molendijk M, Hazes JM, Lubberts E.

RMD Open. 2018 Jan 12;4(1):e000256. doi: 10.1136/rmdopen-2016-000256. eCollection 2018. Review.

25.

Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?

Ten Cate DF, Jacobs JWG, Swen WAA, Hazes JMW, de Jager MH, Basoski NM, Haagsma CJ, Luime JJ, Gerards AH.

Arthritis Res Ther. 2018 Jan 30;20(1):15. doi: 10.1186/s13075-018-1514-2.

26.

Serum Protein N-Glycosylation Changes with Rheumatoid Arthritis Disease Activity during and after Pregnancy.

Reiding KR, Vreeker GCM, Bondt A, Bladergroen MR, Hazes JMW, van der Burgt YEM, Wuhrer M, Dolhain RJEM.

Front Med (Lausanne). 2018 Jan 8;4:241. doi: 10.3389/fmed.2017.00241. eCollection 2017.

27.

Development of a clinical transition pathway for adolescents in the Netherlands.

Walter M, Hazes JM, Dolhain RJ, van Pelt P, van Dijk A, Kamphuis S.

Nurs Child Young People. 2017 Nov 7;29(9):37-43. doi: 10.7748/ncyp.2017.e932.

PMID:
29115764
28.

Absence of ultrasound inflammation in patients presenting with arthralgia rules out the development of arthritis.

van der Ven M, van der Veer-Meerkerk M, Ten Cate DF, Rasappu N, Kok MR, Csakvari D, Hazes JMW, Gerards AH, Luime JJ.

Arthritis Res Ther. 2017 Sep 15;19(1):202. doi: 10.1186/s13075-017-1405-y.

29.

IgA N- and O-glycosylation profiling reveals no association with the pregnancy-related improvement in rheumatoid arthritis.

Bondt A, Nicolardi S, Jansen BC, Kuijper TM, Hazes JMW, van der Burgt YEM, Wuhrer M, Dolhain RJEM.

Arthritis Res Ther. 2017 Jul 5;19(1):160. doi: 10.1186/s13075-017-1367-0.

30.

Cost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice.

Kuijper TM, Buisman LR, Hazes JM, Weel AE.

J Rheumatol. 2017 Jul;44(7):965-967. doi: 10.3899/jrheum.170334. No abstract available.

PMID:
28668812
31.

High-Frame-Rate Power Doppler Ultrasound Is More Sensitive than Conventional Power Doppler in Detecting Rheumatic Vascularisation.

van der Ven M, Luime JJ, van der Velden LL, Bosch JG, Hazes JMW, Vos HJ.

Ultrasound Med Biol. 2017 Sep;43(9):1868-1879. doi: 10.1016/j.ultrasmedbio.2017.04.027. Epub 2017 Jun 20.

32.
33.

Does prednisone use or disease activity in pregnant women with rheumatoid arthritis influence the body composition of their offspring?

de Steenwinkel FDO, Dolhain RJEM, Hazes JMW, Hokken-Koelega ACS.

Reprod Toxicol. 2017 Aug;71:118-123. doi: 10.1016/j.reprotox.2017.05.002. Epub 2017 May 10.

34.

The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Karreman MC, Luime JJ, Hazes JMW, Weel AEAM.

J Crohns Colitis. 2017 May 1;11(5):631-642. doi: 10.1093/ecco-jcc/jjw199. Review.

PMID:
28453761
35.

Doctors' preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment.

Kuijper TM, Folmer R, Stolk EA, Hazes JMW, Luime JJ.

Arthritis Res Ther. 2017 Apr 26;19(1):78. doi: 10.1186/s13075-017-1287-z.

36.

No clear association between ultrasound remission and health status in rheumatoid arthritis patients in clinical remission.

van der Ven M, Kuijper TM, Gerards AH, Tchetverikov I, Weel AE, van Zeben J, Hazes JM, Luime JJ.

Rheumatology (Oxford). 2017 Aug 1;56(8):1276-1281. doi: 10.1093/rheumatology/kex080.

PMID:
28407127
37.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

38.

What support is needed to self-manage a rheumatic disorder: a qualitative study.

Been-Dahmen JM, Walter MJ, Dwarswaard J, Hazes JM, van Staa A, Ista E.

BMC Musculoskelet Disord. 2017 Feb 16;18(1):84. doi: 10.1186/s12891-017-1440-5.

39.

Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?

Pasma A, Schenk C, Timman R, van 't Spijker A, Appels C, van der Laan WH, van den Bemt B, Goekoop R, Hazes JM, Busschbach JJ.

PLoS One. 2017 Feb 2;12(2):e0171070. doi: 10.1371/journal.pone.0171070. eCollection 2017.

40.

Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care.

Karreman MC, Weel AEAM, van der Ven M, Vis M, Tchetverikov I, Nijsten TEC, Wakkee M, Hazes JMW, Luime JJ.

Rheumatology (Oxford). 2017 Apr 1;56(4):597-602. doi: 10.1093/rheumatology/kew410.

PMID:
28013202
41.

Fab glycosylation of immunoglobulin G does not associate with improvement of rheumatoid arthritis during pregnancy.

Bondt A, Wuhrer M, Kuijper TM, Hazes JM, Dolhain RJ.

Arthritis Res Ther. 2016 Nov 25;18(1):274.

42.

Identifying Clinical Factors Associated With Low Disease Activity and Remission of Rheumatoid Arthritis During Pregnancy.

Ince-Askan H, Hazes JMW, Dolhain RJEM.

Arthritis Care Res (Hoboken). 2017 Sep;69(9):1297-1303. doi: 10.1002/acr.23143. Epub 2017 Aug 13.

44.

Adding ultrasound to clinical examination reduced frequency of enthesitis in primary care psoriasis patients with musculoskeletal complaints.

van der Ven M, Karreman MC, Weel AE, Tchetverikov I, Vis M, Nijsten TE, Hazes JM, Luime JJ.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1020-1025. Epub 2016 Sep 8.

PMID:
27749228
45.

Subfertility in Women With Rheumatoid Arthritis and the Outcome of Fertility Assessments.

Brouwer J, Fleurbaaij R, Hazes JMW, Dolhain RJEM, Laven JSE.

Arthritis Care Res (Hoboken). 2017 Aug;69(8):1142-1149. doi: 10.1002/acr.23124. Epub 2017 Jun 26.

46.

Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.

de Jong PH, Hazes JM, Buisman LR, Barendregt PJ, van Zeben D, van der Lubbe PA, Gerards AH, de Jager MH, de Sonnaville PB, Grillet BA, Luime JJ, Weel AE.

Rheumatology (Oxford). 2016 Dec;55(12):2138-2147. Epub 2016 Aug 30.

PMID:
27581208
47.

Psychosocial predictors of DMARD adherence in the first three months of treatment for early arthritis.

Pasma A, Hazes JM, Busschbach JJ, van der Laan WH, Appels C, de Man YA, Nieboer D, Timman R, van 't Spijker A.

Patient Educ Couns. 2017 Jan;100(1):126-132. doi: 10.1016/j.pec.2016.07.019. Epub 2016 Jul 15.

PMID:
27516438
48.

Focus group interviews reveal reasons for differences in the perception of disease activity in rheumatoid arthritis.

Walter MJ, Van't Spijker A, Pasma A, Hazes JM, Luime JJ.

Qual Life Res. 2017 Feb;26(2):291-298. doi: 10.1007/s11136-016-1369-4. Epub 2016 Jul 21.

49.
50.

Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients.

Pasma A, den Boer E, van 't Spijker A, Timman R, van den Bemt B, Busschbach JJ, Hazes JM.

Rheumatology (Oxford). 2016 Oct;55(10):1812-9. doi: 10.1093/rheumatology/kew247. Epub 2016 Jun 27.

PMID:
27354686

Supplemental Content

Loading ...
Support Center